Safety and Efficacy of Stem Cell Therapy in Patients with Retinal Degenerative Diseases

The primary objective of this study is to evaluate the safety of stem cells in the management of retinal degenerative diseases. Establishing the safety profile of such interventions is a critical clinical requirement to ensure that cellular therapies do not induce adverse events or exacerbate underlying pathology. Secondary objectives are not specified.

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with retinal degenerative diseases. The cohort includes both males and females within the age range of 3 to 10 years.

This Phase 3 clinical trial utilizes a methodology to evaluate the safety of stem cells in the treatment of retinal degenerative diseases. The study design is structured to monitor clinical outcomes over an estimated period spanning from March 2026 to February 2028. The research protocol begins with a screening visit to determine eligibility based on predefined criteria. Following the initial assessment, participants undergo a sequence of scheduled follow-up visits to monitor physiological responses and safety parameters. The procedure concludes with an end-of-study visit to collect final data. Total participant involvement is dictated by the specified study timeline, although early termination may occur according to established protocol safety guidelines.

The assessment of efficacy in this phase 3 clinical trial involves the evaluation of clinical parameters related to retinal degenerative diseases. Specific methodologies for measuring therapeutic impact and the scheduled timepoints for data collection are determined by the study protocol.